Adimab

Lebanon, New Hampshire, United States ·Founded 2007

Overview

Adimab's yeast-based discovery platform functions as a synthetic human immune system to create novel antibody therapeutics across an extensive range of diseases, including cancer as well as autoimmune and infectious diseases. We are a profitable privately-held biotech company, backed by top-tier venture capital firms including Google Ventures, OrbiMed Advisors, Polaris Partners, and SV Life Sciences. We are unique in our ability to take a long-term view on value creation which allows us to continuously refine and improve our technology and make substantial investments in R&D.

Get the full list of 54,000+ investors

Adimab and every other firm and angel in the database — as one spreadsheet you keep.

$19one-time payment · no subscription
  • All 54,000+ investors — VC firms, private equity, family offices and angels
  • The key person to contact at each one, with their job title
  • Their work email address
  • Their phone number
  • Their LinkedIn profile
  • Delivered as a single .xlsx file — download it as many times as you like
Get the full list — $19 → One payment. No seats, no credits, no expiry. Already bought it? Sign in to download it again — no second payment.

Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.

Frequently asked questions about Adimab

Who are the partners at Adimab?

Team members listed for Adimab include Jessica Dawson (Assoc. Director).

How do I contact Adimab?

Adimab's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.

Last updated · Source: ConnectSafely investor database